Latest news with #S-3
Business Wire
29-07-2025
- Business
- Business Wire
Sidus Space Announces Closing of Public Offering
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), an innovative, agile space and defense technology company providing flexible, cost-effective solutions to government, defense, intelligence, and commercial companies around the globe, today announced the closing of its previously announced best-efforts public offering of 7,143,000 shares of its Class A common stock. Each share of Class A common stock was sold at a public offering price of $1.05 per share for gross proceeds of approximately $7.5 million, before deducting the placement agent's fees and offering expenses. All of the shares of common stock were offered by the Company. The Company intends to use the net proceeds from the offering for (i) sales and marketing, (ii) operational costs, (iii) product development, (iv) manufacturing expansion and (v) working capital and other general corporate purposes. 'This offering, coupled with our recently announced launch of our dual-use Fortis™ VPX product line with integrated AI/ML processing, positions Sidus to focus on significant growth opportunities.' said Carol Craig, the Company's Chief Executive Officer. Adarsh Parekh, Chief Financial Officer, added, 'The additional capital bolsters our liquidity, allowing our team to fully focus on the execution of our strategy and high growth initiatives that we expect will drive real outcomes for our customers.' ThinkEquity acted as sole placement agent for the offering. The securities were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-273430), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC') on July 26, 2023 and declared effective on August 14, 2023. The offering was made by means of a written prospectus. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and made available on the SEC's website. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Sidus Space Sidus Space (NASDAQ: SIDU) is an innovative, agile space and defense technology company offering flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space system and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida's Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Sidus Space's prospectus supplement and Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Business Wire
28-07-2025
- Business
- Business Wire
Verisign Announces Secondary Offering of Common Stock by Selling Stockholders
RESTON, Va.--(BUSINESS WIRE)--VeriSign, Inc. (NASDAQ: VRSN) (the 'Company'), a global provider of critical internet infrastructure and domain name registry services, today announced the launch of an underwritten secondary offering (the 'Offering') by affiliates of Berkshire Hathaway Inc. ('Berkshire Hathaway'), of 4,300,000 shares of the Company's common stock, par value $0.001 per share ('Common Stock'). The selling stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is sized in order to reduce Berkshire Hathaway's beneficial ownership of the Company below the ten percent threshold that triggers additional regulatory obligations. Affiliates of Berkshire Hathaway have been stockholders of the Company since 2012, and Berkshire Hathaway has voluntarily agreed with J.P. Morgan Securities LLC (the 'Underwriter') that the remaining shares of Common Stock beneficially owned by Berkshire Hathaway and its affiliates following the Offering will be subject to a 365-day lock-up agreement. The Underwriter is acting as the sole underwriter of the Offering. The selling stockholders also expect to grant the Underwriter a 30-day option to purchase up to an additional 515,032 shares of Common Stock. The Offering will be made by means of a prospectus supplement and the accompanying base prospectus, which was filed as part of an automatic shelf registration statement on Form S-3 (File No. 333-288995), which was filed with the Securities and Exchange Commission (the 'SEC') and became effective on July 28, 2025. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and the Offering. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering, as well as copies of the final prospectus supplement once available, may be obtained for free on the SEC's website at or by contacting: J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@ and postsalemanualrequests@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Verisign Verisign (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, enables internet navigation for many of the world's most recognized domain names. Verisign helps enable the security, stability, and resiliency of the Domain Name System and the internet by providing root zone maintainer services, operating two of the 13 global internet root servers, and providing registration services and authoritative resolution for the .com and .net top-level domains, which support the majority of global e-commerce. Statements in this announcement other than historical data and information constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve risks and uncertainties that could cause our actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, the closing of the Offering on the terms described, or at all. More information about potential factors that could affect our business and financial results is included in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Verisign undertakes no obligation to update any of the forward-looking statements after the date of this announcement. ©2025 VeriSign, Inc. All rights reserved. VERISIGN, the VERISIGN logo, and other trademarks, service marks, and designs are registered or unregistered trademarks of VeriSign, Inc. and its subsidiaries in the United States and in foreign countries. All other trademarks are property of their respective owners.
USA Today
14-07-2025
- Business
- USA Today
Mizuno Pro S-1 irons: A modern muscleback forged for precision and solid feel
The Mizuno Pro S-1 irons offer a pure muscleback design with refined feel, stability, and tour-inspired shaping. Gear: Mizuno Pro S-1 irons Price: $1,400 (7-piece set) with KBS Tour 120 stiff shafts and Golf Pride Tour Velvet grips Specs: Grain Flow Forged HD 1025E mild carbon steel, Channel Back design, copper underlay, Harmonic Impact Technology Available: Pre-sale begins August 28; retail release September 11 Who it's for: Elite golfers who prioritize feel, precision, and control above all else and prefer a compact, pure muscleback iron with modern sole geometry. What you should know: The Mizuno Pro S-1 brings classic forged feel and shaping to a modern muscleback with refined sole geometry, enhanced vertical stability, and a satisfyingly solid feel preferred by discerning ballstrikers. It blends seamlessly with the S-3's Signature Series while having sharper shaping and tour-validated sole refinements. The Deep Dive: The Mizuno Pro S-1 irons continue a tradition of precision-forged, tour-inspired blades with subtle yet meaningful updates that make them more playable and more refined — without losing the DNA that's earned Mizuno its reputation among ball-strikers. Where the Mizuno Pro S-3 irons that were released in 2024 provided a tiny bit of forgiveness through a subtle cavity-back and multi-material construction, the S-1 is a pure muscleback for elite players who want control, workability, and a direct connection to the golf ball. But this is more than a nostalgic blade—it's a modern, optimized evolution. The S-1 is forged from a single billet of 1025E Pure Select mild carbon steel using Mizuno's Grain Flow Forged HD process in Hiroshima, Japan, creating a tight grain structure for that buttery-soft feel Mizuno fans expect. A thin copper underlay sits beneath the chrome plating to subtly soften vibrations, enhancing feedback without sacrificing a crisp, solid sensation through impact. What distinguishes the S-1 is the Channel Back design, which strategically repositions mass behind the face to promote greater vertical stability and a more consistent center of gravity. This tweak yields more consistent launch and control, especially on slightly mishit shots, without compromising the look of a traditional muscleback. Harmonic Impact Technology (H.I.T.) returns with fine-tuned vibration frequencies that produce a slightly firmer, yet satisfyingly-solid feel at impact. It's designed for players who want auditory and tactile feedback that breeds confidence with each strike. Visually, the S-1 stands out with a square toe shape, a look that has gained popularity on tour and resonates with players like staffers Keith Mitchell and Ben Griffin. Compared to the more rounded S-3, the S-1 has a more compact, squared-off profile, especially in the scoring clubs, to create a sharper, more defined look at address. The sole geometry — refined with input from tour players — features a flatter camber, sharpened leading edge, and an extra degree of bounce compared to the S-3. This combination smooths out turf interaction, particularly for players with a shallower angle of attack, and helps avoid digging while maintaining the ability to play aggressively off tight lies. Available in 4-PW for both right- and left-handed players, the S-1 comes standard with KBS Tour 120 stiff shafts and Golf Pride Tour Velvet grips. The loft progression starts at 24 degrees in the 4-iron and ends at 46 degrees in the pitching wedge, keeping pace with modern gapping expectations while maintaining classic feel and control. In the end, the S-1 isn't about chasing distance—it's about delivering precision, consistent launch, and the kind of refined feedback that players at the top of their game demand. Where the S-3 catered to elite ball-strikers who wanted a bit of help, the S-1 is for those who want nothing to come between them and the golf ball.
Business Wire
24-06-2025
- Business
- Business Wire
Forte Biosciences Announces Proposed Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in the offering. All of the shares of common stock and pre-funded warrants are being offered by Forte. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical and preclinical development of its product candidate and other research activities. TD Cowen, Evercore ISI, Guggenheim Securities and Chardan are acting as joint book-running managers for the offering. Lucid Capital Markets is acting as co-manager for the offering. The offering is being made pursuant to a Registration Statement on Form S-3 (File No. 333-286226), including a base prospectus, previously filed with and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and copies of which, when available, can be accessed for free through the SEC's website at Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888)-474-0200, or by email at Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ and Chardan Capital Markets, LLC, One Pennsylvania Plaza, Suite 4800, New York, NY 10119. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding the completion, timing, and size of the offering, Forte's intent to grant the underwriters a 30-day option to purchase additional shares, and the anticipated use of proceeds from the offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not Forte will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting Forte's business and operating results are contained in Forte's Quarterly Report on Form 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Yahoo
23-06-2025
- Business
- Yahoo
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ('Cidara') (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the 'SEC') on May 8, 2025, and declared effective by the SEC on May 15, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@ Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@ Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ or Cantor Fitzgerald & Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at prospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration, and Cidara announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. Forward-Looking Statements Statements contained in this press release regarding Cidara's expectations regarding the offering are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Cidara's expectations regarding the completion, timing and size of the proposed offering and with respect to granting the underwriters a 30-day option to purchase additional shares. Forward-looking statements are based upon Cidara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with market conditions and the satisfaction of closing conditions related to the proposed public offering and risks and uncertainties associated with Cidara's business and finances in general. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Cidara's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Cidara's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact: Brian RitchieLifeSci Advisors(212) 915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
